FindTrial
Sign In

Placebo (PBO)

DRUG5 trials

Sponsors

Merck Sharp & Dohme LLC, Hoffmann-La Roche, Novartis Pharmaceuticals, Ridgeback Biotherapeutics, LP, VA Office of Research and Development

Conditions

Hepatitis C, ChronicPTSD - Post Traumatic Stress DisorderRheumatoid ArthritisSARS-CoV-2 Infection, COVID-19Spondylitis, Ankylosing

Phase 2

Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)
CompletedNCT00704405
Merck Sharp & Dohme LLCHepatitis C, Chronic
Start: 2009-03-27End: 2012-09-10Updated: 2018-10-09
Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19
CompletedNCT04405570
Ridgeback Biotherapeutics, LPSARS-CoV-2 Infection, COVID-19
Start: 2020-06-19End: 2021-02-21Updated: 2022-02-16
Written Exposure Therapy Plus Adjunctive Methylphenidate Treatment for Veterans With PTSD
Not yet recruitingNCT07904000
VA Office of Research and DevelopmentPTSD - Post Traumatic Stress Disorder
Start: 2027-07-01End: 2030-09-30Target: 138Updated: 2026-10-29

Phase 3

A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
CompletedNCT01855789
Hoffmann-La RocheRheumatoid Arthritis
Start: 2013-11-07End: 2016-10-14Updated: 2017-12-26
Extension in AS: Sustainability of Benefits, Safety and Tolerability
CompletedNCT01863732
Novartis PharmaceuticalsSpondylitis, Ankylosing
Start: 2013-11-06End: 2018-03-16Updated: 2019-07-30

Related Papers

Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates
UNC Libraries2022-11-24
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
The Lancet Infectious Diseases2022-10-1975 citations
Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications
Rheumatology and Therapy2022-03-1933 citations
Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates
Clinical Infectious Diseases2021-11-198 citations
Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
Antibiotics2021-10-2385 citations
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
Rheumatology and Therapy2020-12-2213 citations
Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.
2020-12-03308 citations
Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1
Frontiers in Immunology2020-11-265 citations
Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study
RMD Open2019-09-0180 citations
Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
Lara D. Veeken2018-11-06136 citations
Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.
2013-10-1018 citations